hsa-miR-92b-5p高表达预测低级别胶质瘤放射抗拒的相关研究  

The study about low-grade glioma radioresistance prediction based on the high hsa-miR-92b-5p expression

作　　者：何璐 郭伟盛 闫冰川 He Lu;Guo Weisheng;Yan Bingchuan(Department of Radiotherapy,Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;The Second Department of Integrated Traditional and Western Medicine,Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China)

机构地区：[1]广州医科大学附属肿瘤医院放疗科,广州510095 [2]广州医科大学附属肿瘤医院中西医结合二科,广州510095

出　　处：《中华生物医学工程杂志》2023年第6期656-660,共5页Chinese Journal of Biomedical Engineering

基　　金：国家自然科学基金项目(81602067)。

摘　　要：探讨hsa-miR-92b-5p表达水平对低级别胶质瘤患者肿瘤放射敏感性的预测价值。在接受放射治疗的低级别胶质瘤患者中肿瘤组织hsa-miR-92b-5p高表达患者总体生存[5年生存率:(45.8±5.9)%比(64.1±6.9)%;P<0.001]与无进展生存[5年无进展生存率:(24.1±5.5)%比(56.6±6.6)%;P<0.001]均显著低于hsa-miR-92b-5p低表达患者。说明hsa-miR-92b-5p高表达提示低级别胶质瘤放射抗拒,其在指导低级别胶质瘤个体化治疗方面具有潜在的临床应用价值。To investigate the predictive value of hsa-miR-92b-5p expression for radiosensitivity in patients with low-grade glioma.For low-grade glioma patients received radiotherapy,the overall survival and the progression-free survival of the patients with high hsa-miR-92b-5p expression was significantly lower than that of the patients with low hsa-miR-92b-5p expression[5-year survival rate:(45.8±5.9)%vs(64.1±6.9)%,P<0.001;5-year progression-free survival rate:(24.1±5.5)%vs(56.6±6.6)%,P<0.001].The high expression of hsa-miR-92b-5p suggested radioresistance of low-grade glioma.The expression of hsa-miR-92b-5p had potential to be a radioresistance biomarker to guide the individualized treatment of low-grade glioma.

关 键 词：胶质瘤 微RNA 预后 放射敏感性 分子标志物 

分 类 号：R739.4[医药卫生—肿瘤]